VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 09, 2019 08:00 ET | VBI Vaccines, Inc.
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...
VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B
December 06, 2018 08:00 ET | VBI Vaccines, Inc.
Upon closing, VBI received gross proceeds of $11 million, consisting of an upfront payment and an equity investment at $3.05 per share from Brii BiosciencesVBI is eligible to receive an additional...